Carolien Zeetsen

116 Results Patient characteristics Data of 103 patients were analysed in this study, this included 80 MoCA measurements at T1 and 62 at T2. In total 39 patients had completed the MoCA at both T1 and T2. These 39 patients did not differ from patients with a MoCA on either T1 or T2 regarding sex, age, GHB dose, length of daily GHB use, number of comas and MoCA performance. The mean age was 28.5 years ( SD = 6.47) and 68% were men. The mean duration of daily GHB use was 31.3 months ( SD = 32.61), with a mean of 89.9 ml GHB per day ( SD = 52.60). GHB–induced comas were common, with 41.4% reporting 5 or less GHB comas, 18.4% between 6 and 19 times, 19.5% between 20 and 50 times, and 20.7% reported to have experienced more than 50 comas in their lifetime. The highest reported co–morbid substance of use in the past 30 days was nicotine (83,7%), followed by stimulants (50%), alcohol (43,5%), cannabis (33,7%) and cocaine (33,7%), respectively. Performance on the Montreal Cognitive Assessment On average, patients scored a MoCA–TS of 24.2 points ( SD = 3.01) at T1 and 25.8 points ( SD = 2.78) at T2, with a trend towards significance (Wilks’ λ = .90, F (1, 38) = 4.08, p = .051) for patients with a MoCA on both T1 and T2 (Table 6.1). Fewer patients scored below the cut–off score on T2 than on T1, indicating an improvement ( χ 2 (1) = 5.21 p = .022). In total 27 patients improved their scores between T1 and T2, 5 had the same score and 7 had a lower score. On domain level, patients performed lowest on Memory and highest on Orientation on both T1 and T2. No significant differences were observed on domain level between T1 and T2. Correlation between cognitive performance, and GHB use characteristics MoCA–TS on both T1 and T2 did not correlate significantly with any of the investigated GHB use characteristics (i.e. the number of comas, GHB dose, total length of GHB use, length of daily GHB use and the GHB exposure score; Table 6.2). There was only a significant correlation between sex and scoring above or below the MoCA cut–off (Table 6.3). Relation between cognitive performance and relapse Non–relapse patients at T3 scored higher on the MoCA–DS attention, memory and MoCA–TS at T1 in comparison to patients who had relapsed at T3. Also, more of the non–relapse patients scored above the MoCA–TS cut off–score at T1, compared to patients who relapsed at T3. No relationship was found between treatment outcome (relapse or non–relapse) and cognitive performance (MoCA–DS or –TS) on T2 (Table 6.4).